Post-earnings recap
Reported
Tue, Jul 21, 2026
EPS actual
$2.41
EPS est.
$2.19
EPS surprise
+9.79%
1-day move
+2.88%
Novartis AG reported better-than-expected earnings per share, which led to a positive stock reaction, increasing by 2.88%. However, there was no revenue data provided, and no guidance updates were given. Investors may view the EPS beat as a sign of underlying strength in the company's performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $2.41 | N/A | +9.79% |
| Revenue | N/A | N/A | N/A |
No transcript is on record, and the analysis is based on numerical results only.
Novartis AG (NVS) is a global healthcare company that focuses on developing and manufacturing innovative pharmaceuticals. With a market cap of $288 billion, it plays a significant role in the healthcare sector, particularly in areas like oncology, cardiovascular, and neuroscience.
Last quarter
In Q1-2026, Novartis reported an EPS of $1.99, which was below the expected $2.11, resulting in a slight stock increase of 0.91% the following day. The company has shown mixed results in previous quarters, with a history of both beats and misses.
EPS beat streak
1Q
EPS beat rate
75%
Avg EPS surprise
+4.23%
Avg 1-day reaction
-0.69%
Overall, expectations for Novartis are cautious, with investors closely watching for any signs of recovery in earnings and revenue growth. The company's ability to meet or exceed last quarter's EPS will be a focal point.
Bull case
If Novartis can demonstrate strong revenue growth and successful pipeline advancements, it could lead to a positive reassessment of its stock. A beat on EPS could also boost investor confidence.
Bear case
Conversely, if the company reports another earnings miss or provides weak guidance on its drug pipeline, it could lead to further declines in stock price and investor sentiment.
The print will turn on these.
Q1
What is the updated guidance for EPS and revenue growth for the upcoming quarters?
Given the recent earnings miss, guidance will be crucial for setting investor expectations and assessing the company's recovery trajectory.
Q2
How is the pipeline progressing, particularly for key drugs expected to launch?
Pipeline developments can significantly influence future revenue and investor confidence, making this a critical area of focus.
—
Est. EPS
$0.41
Est. Rev
$318.0B
Impl. Move
±16.8%
Why consensus could be wrong
The Street may be underestimating the potential for Novartis to surprise on the upside due to recent pipeline advancements that have not been fully factored into earnings expectations.
Supporting evidence
The options market is pricing a ±9.59% move, indicating higher volatility expectations that may not align with historical performance.
Despite recent misses, Novartis has a strong track record of beating EPS estimates 75% of the time, suggesting potential for a positive surprise.
The put/call ratio at 1.10 indicates a slight bearish sentiment, which could mean the market is overly cautious.
Key risk
If the company provides strong updates on its drug pipeline, it could significantly shift investor sentiment.
Pre-commit to what would confirm each case.
This quarter's performance is pivotal for Novartis, as it seeks to regain investor confidence after recent mixed results.
Bull confirmed if
An EPS of $2.11 or higher, alongside positive commentary on pipeline drugs, would confirm the bull case.
Bear confirmed if
An EPS below $1.95 and negative guidance on revenue growth would confirm the bear case.
What the market is pricing for the move.
Implied Move
±9.59%
Historical Avg
±2.3%
The options market is pricing in a significant potential move, suggesting that investors expect volatility around the earnings announcement.
Options are pricing ±9.6% while NVS has averaged ±2.3% over the last 8 prints — setup is pricing rich.
ATM IV
0.3%
30d HV
20.0%
Smart-money positioning from the most recent 13F filings.
Institutional
7.27%
of float
Insider
0.01%
of float
Holders
1,806
institutions
Top Holders· as of Jun 2026
Fisher Asset Management, LLC
15,523,378 sh · $2.2B
0.76%
11.8%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Novartis beats expectations, history suggests a potential stock increase of around 2.49%, confirming a positive outlook.
In line / cautious
If results are in line with expectations but cautious commentary is provided, the stock may react neutrally, reflecting ongoing investor uncertainty.
Miss
A miss on earnings could lead to a decline of about 1.76%, further dampening investor sentiment.
House and Senate STOCK Act disclosures over the trailing 6 months.
Trades
1
0 buys·1 sell
Members
1
House only
Est. Notional
$15,001.00–$50,000.00
disclosed dollar ranges
Most Active Members
1 trade
The lines on the call that would change the story.
Morgan Stanley
8,726,827 sh · $1.3B
0.43%
2.3%
Dimensional Fund Advisors LP
8,117,586 sh · $1.2B
0.40%
0.1%
Primecap Management Company
6,592,124 sh · $944.5M
0.32%
-12.9%
LOOMIS SAYLES & CO L P
5,239,309 sh · $750.7M
0.26%
-3.4%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.
Net selling
Recent Transactions
Traded Aug 27, 2026 · disclosed Sep 25, 2026
$15,001.00–$50,000.00
Filed 30–45+ days after the trade. Treat as positional context, not a leading indicator. Amounts are SEC-mandated dollar ranges, not exact values.